The firm is developing a portable, rapid MDx platform for infectious disease testing in clinics, and anticipates launching a first product in 2020.
The test for P. vivax-associated malaria was developed with support from FIND and will be distributed by Human Diagnostics Worldwide.
The test can detect resistance to two of the most commonly prescribed antibiotics used to treat strep throat, and could potentially be adapted for point-of-care use.
The researchers said that affordable tests that can differentiate malaria from similar diseases is vital for administering the most targeted treatment for patients.
The Polish company recently received 9 million Polish złoty ($2.4 million) from the country's National Center for Research and Development to support its activities.
Meridian's diagnostics revenues grew 1 percent year over year to $36.4 million while its life science revenues jumped 8 percent to $15.4 million.
The San Diego-based company is ramping up efforts to market its handheld molecular influenza test in anticipation of the upcoming flu season.
The funding totals up to $5.6 million over five years and will incorporate Talis' proprietary SlipChip technology.
The award will go toward development of Talis Bio's SlipChip POC technology for pathogen identification and antibiotic-susceptibility testing.
In Life Sciences, CEO Thomas Joyce noted a strong performance by Beckman Coulter, while in Diagnostics, he said Cepheid grew 25 percent year over year.